Brokerages expect Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) to announce $0.09 earnings per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Ironwood Pharmaceuticals’ earnings, with estimates ranging from $0.03 to $0.12. Ironwood Pharmaceuticals posted earnings of ($0.38) per share in the same quarter last year, which would suggest a positive year over year growth rate of 123.7%. The firm is scheduled to announce its next earnings results on Tuesday, November 5th.
According to Zacks, analysts expect that Ironwood Pharmaceuticals will report full year earnings of ($0.08) per share for the current year, with EPS estimates ranging from ($0.26) to $0.01. For the next fiscal year, analysts anticipate that the business will post earnings of $0.52 per share, with EPS estimates ranging from $0.18 to $1.08. Zacks’ EPS averages are a mean average based on a survey of research firms that that provide coverage for Ironwood Pharmaceuticals.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.08 EPS for the quarter, topping the consensus estimate of ($0.07) by $0.15. The firm had revenue of $102.22 million for the quarter, compared to the consensus estimate of $89.28 million. The company’s revenue was up 26.0% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.22) EPS.
In other news, President Thomas A. Mccourt sold 220,000 shares of the company’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $9.24, for a total value of $2,032,800.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Halley E. Gilbert sold 20,000 shares of the company’s stock in a transaction on Friday, July 26th. The shares were sold at an average price of $10.00, for a total transaction of $200,000.00. The disclosure for this sale can be found here. Insiders sold a total of 240,212 shares of company stock worth $2,234,716 over the last ninety days. Insiders own 5.90% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in IRWD. Macquarie Group Ltd. purchased a new stake in Ironwood Pharmaceuticals during the second quarter worth $1,295,000. United Services Automobile Association boosted its holdings in Ironwood Pharmaceuticals by 3.9% during the second quarter. United Services Automobile Association now owns 225,058 shares of the biotechnology company’s stock worth $2,462,000 after buying an additional 8,500 shares in the last quarter. ClariVest Asset Management LLC purchased a new stake in Ironwood Pharmaceuticals during the second quarter worth $1,455,000. Nuveen Asset Management LLC purchased a new stake in Ironwood Pharmaceuticals during the second quarter worth $10,126,000. Finally, AQR Capital Management LLC boosted its holdings in Ironwood Pharmaceuticals by 181.9% during the second quarter. AQR Capital Management LLC now owns 149,888 shares of the biotechnology company’s stock worth $1,640,000 after buying an additional 96,719 shares in the last quarter.
Shares of NASDAQ IRWD traded down $0.19 during trading hours on Friday, hitting $8.85. 32,678 shares of the stock were exchanged, compared to its average volume of 2,218,924. Ironwood Pharmaceuticals has a 12 month low of $8.40 and a 12 month high of $19.36. The company has a market cap of $1.48 billion, a PE ratio of -9.36 and a beta of 1.79. The firm has a fifty day moving average price of $9.27 and a 200-day moving average price of $10.91.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.